ClinicalTrials.gg
RecruitingNCT06471634Updated Mar 27, 2025

A Study Looking to Improve Sleep and Reduce Sedentary Behaviour in Those Living With Type 2 Diabetes Mellitus

An interventional study of CBTi and Control - usual care in Diabetes Mellitus, Type 2, Insomnia and Sedentary Behavior, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by University of Leicester · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Leicester.

Planned enrollment
6th of 12
44 · median 44
Started
2024
with 2 others
No phase
6 of 23
1 open now
Registered
22nd of 23
by date

Among the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 with no phase, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, or all of them as a file.
02

Study summary

The goal of this clinical feasibility trial is to learn whether the investigators can improve sleep and reduce sedentary behaviour in people living with Type 2 diabetes mellitus with sleep problems. The main questions it aims to answer are: • question 1, can objectively measured sleep and sedentary behaviour be improved in the participants and • question 2, what effect will this have on a number of physical and physiological markers. Participants in the intervention group will be asked to keep sleep diaries and attend regular meetings with a qualified coach who will use a specific talking therapy to try to improve sleep and with use behaviour change techniques to help them be less sedentary. Researchers will compare the control group to the intervention group to see if effects differ between groups.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Insomnia
  • Sedentary Behavior

Keywords

  • Sleep
  • Insomnia
  • Sedentary behaviour
  • Diabetes Mellitus, Type 2
  • Cognitive Behaviour Therapy insomnia (CBTi)
  • Behaviour change
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Diabetes Mellitus type 2 for longer than 3 months
  • Participant is willing and able to give to take part in the study.
  • Sleep disorder symptom checklist 25 (SDS-CL-25) of ≥5 on insomnia criteria.
  • Not at high risk of undiagnosed Obstructive Sleep Apnoea (OSA), scoring ≥5 on STOP BANG scale (snoring, tired, observed, pressure, , age, neck size, gender) diagnosed treated OSA is acceptable.
  • (HbA1c) of 10% or less (86 mmol/mol) or less
  • Male or Females.
  • ≥ 18 ≤ 75 years of age.
  • Able to walk without the use of an assistive device or requiring assistance from another person.
  • Not undertaking more than 75 minutes a week of strenuous exercise or sport.
  • Not taking opioids
  • Be treatment stable for at least 3 months
  • Accelerometer measurement of SE ≤ 85%
  • An understanding that CBTi may exacerbate sleep deprivation in the short term which may impact on certain aspects of daily life.

Exclusion criteria

Exclusion Criteria:

  • Individuals living with narcolepsy or diagnosed parasomnia
  • Individuals with type 1 diabetes or gestational diabetes
  • Recent cardiovascular event (within the last 6 months).
  • Currently on opioids
  • Diagnosed with borderline personality disorder, psychosis, adult attention deficit hyperactivity disorder (ADHD) or schizophrenia (self-reported).
  • Individuals living with epilepsy or seizures.
  • Shift workers
  • Female participant planning to become pregnant with the timeframe of the study or is currently pregnant.
  • Terminal illness.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    CBTi and Sedentary Behaviour support

    Participants will be counselled in how to improve their sleep and decrease sedentary behaviour using CBTi and behaviour change techniques.

    Behavioral: CBTi · Behavioral: Sedentary behaviour reduction

  • Active comparator
    Control - usual care

    Participants will be given a leaflet containing brief information on good sleep hygiene practice and the benefits of decreasing sedentary behaviour.

    Other: Control - usual care

Interventions

  • BehavioralCBTi

    A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

  • OtherControl - usual care

    Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

  • BehavioralSedentary behaviour reduction

    Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.

06

What researchers measure

Primary outcomes

  1. Sleep Efficiency (SE) measured using accelerometer data.

    The primary outcome measure is change in objectively measured SE in the intervention arm compared to the control group.

    Time frame: Before and after the 12 week intervention/intervention period

Secondary outcomes

  1. Objectively measured sleep - sleep onset latency

    Accelerometer data will be used to measure sleep onset latency in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  2. Objectively measured sleep - wake after sleep onset

    Accelerometer data will be used to measure wake after sleep onset in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  3. Objectively measured sleep - total sleep time

    Accelerometer data will be used to measure total sleep time in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  4. Objectively measured sleep - sleep duration variability

    Accelerometer data will be used to measure sleep duration variability in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  5. Objectively measured sleep - sleep midpoint variability

    Accelerometer data will be used to measure sleep midpoint variability in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  6. Objectively measured sedentary behaviour

    Accelerometer data will be used to measure total time spent in sedentary time in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  7. Objectively measured physical activity

    Accelerometer data will be used to measure total time spent in physical activity in minutes.

    Time frame: Before and after the 12 week intervention/intervention period

  8. Subjectively measured sleep - insomnia

    The Insomnia Severity index, will be used to measure the level of insomnia - it is a questionnaire and has a range of 0-28 with higher scores indicating more insomnia.

    Time frame: Before and after the 12 week intervention/intervention period

  9. Subjectively measured sleep quality -

    The Pittsburgh Sleep Quality Index will be used to measure subjective sleep quality, this is a questionnaire and has a range of 0-21 with higher scores indicating worse sleep quality.

    Time frame: Before and after the 12 week intervention/intervention period

  10. Subjectively measured sleepiness

    Epworth Sleepiness Scale is a questionnaire and has a range of 0-24 with higher scores indicating more sleepiness.

    Time frame: Before and after the 12 week intervention/intervention period

  11. Measurement of fatigue

    The Functional assessment of chronic illness therapy (FACIT) scale will be used to subjectively measure fatigue, the range is 0-52 with higher scores indicating less fatigue.

    Time frame: Before and after the 12 week intervention/intervention period

  12. Blood pressure

    Blood pressure (both diastolic and systolic) will be measured using an automatic electronic device and the units used will be millimetres of mercury.

    Time frame: Before and after the 12 week intervention/intervention period

  13. Fasting blood glucose

    Fasting measured via a venous sample and in millimoles per litre (Mmol/L)

    Time frame: Before and after the 12 week intervention/intervention period

  14. Continuous blood glucose

    Continuous blood glucose measured via a continuous glucose monitor and in Mmol/L (Mmol/L)

    Time frame: Before and after the 12 week intervention/intervention period

  15. Insulin

    Insulin will be measured via a venous sample and in micro units per millilitre.

    Time frame: Before and after the 12 week intervention/intervention period

  16. Triglycerides

    Triglycerides will be measured via a venous sample and in Mmol/L.

    Time frame: Before and after the 12 week intervention/intervention period

  17. Cholesterol

    Cholesterol, including Low density lipoprotein and high density lipoprotein and total cholesterol, will be measured via a venous sample and in Mmol/L

    Time frame: Before and after the 12 week intervention/intervention period

  18. Physical function - the short physical performance battery

    The short physical performance battery consists of 3 physical tests, with a total score range of 0-12 with higher scores indicating better physical function.

    Time frame: Before and after the 12 week intervention/intervention period

  19. Physical function - the sit to stand-60

    The sit to stand-60 is the number of times the participant can rise from sit to stand in one minute using a designated chair with no arms and without the use of the participants arms, and is reported as a number.

    Time frame: Before and after the 12 week intervention/intervention period

  20. Physical and Cognitive function - The World Health Organisation Disability Assessment schedule (WHODAS)

    WHODAS is a questionnaire used to assess both physical and cognitive function. Each question is scored 0-4, scores are then averaged for all the questions so the range is 0-4 and the higher the score the more difficulty the participant is experiencing in functioning.

    Time frame: Before and after the 12 week intervention/intervention period

  21. Cognitive function - verbal fluency test

    Cognitive function will be measured using the verbal fluency test, which is conducted over two 60s periods and is scored by the number of correct answers.

    Time frame: Before and after the 12 week intervention/intervention period

  22. Quality of life- European Quality of Life 5 dimension (EQ-5D-5L)

    EQ-5D-5L, the five questions are scored 1-5 and each represents a different aspect, it is presented as a five digit number representing each domain. The higher the numbers, the worse quality of life.

    Time frame: Before and after the 12 week intervention/intervention period

  23. Weight

    Weight in kilograms will be measured.

    Time frame: Before and after the 12 week intervention/intervention period

  24. Height

    Height in metres will be measured.

    Time frame: Before and after the 12 week intervention/intervention period

  25. Body mass index (BMI)

    BMI will be calculated using weight and height to produce BMI in kg/m\^2

    Time frame: Before and after the 12 week intervention/intervention period

  26. Body composition - via bioimpedance

    Bioimpedance scales will be used to measure body composition including percentage fat, muscle mass and water

    Time frame: Before and after the 12 week intervention/intervention period

  27. Depression - The Patient Health Questionnaire-9 (PHQ9)

    PHQ9 will be used to measure depressive symptoms. The PHQ9 has a range of 0-27 with higher scores indicating more depressive symptoms/depression.

    Time frame: Before and after the 12 week intervention/intervention period

  28. Anxiety - The General Anxiety Disorder Assessment-7 (GAD7)

    GAD7 will be used to measure anxiety symptoms. It has a range of 0-21, with higher scores indicating more anxiety.

    Time frame: Before and after the 12 week intervention/intervention period

  29. Food intake - food diaries

    3 Day food diaries will be used to measure food intake.

    Time frame: Before and after the 12 week intervention/intervention period

07

Study locations

1 of 1 sites recruiting
  • Diabetes Research Centre University Hospitals Leicester
    Leicester, Leicestershire LE5 4PW, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data in anonymised form may be suitable for sharing at the end of the trial. Should there be concerns about protecting the identity of participants/commercialisation of outputs, access restrictions will need to be considered. If suitable, anonymised data may be added to UoL's Research Archive (https://figshare.le.ac.uk/) within 6 months of the trial end date. The repository is registered in OpenDOAR and preserves research outputs (minimum of 10 years).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2026, 22 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 22 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 24, 2024
StartActual
Sep 2, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471634
Collaborators
University Hospitals, Leicester
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Sep 2, 2024
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Mar 27, 2025

Study contacts

Alix HA Covenant, MSc
Contact
ahac1@leicester.ac.uk
01162588572
Joe Henson, PhD
Contact
jjh18@leicester.ac.uk
1162588572
Melanie Davies, PhD
principal investigator · Leicester Diabetes Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion